✦ LIBER ✦

Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer

✍ Scribed by Martee L. Hensley; Dore Lebeau; L.F. Leon; E. Venkatraman; Roger Waltzman; Paul Sabbatini; Lois Almadrones; Dennis Chi; David Spriggs

Book ID: 112248485
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 51 KB
Volume: 81
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2001.6185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence and risk factors for paclitaxe

Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

✍ Toshiaki Sendo; Naoko Sakai; Yoshinori Itoh; Hiroaki Ikesue; Hiroaki Kobayashi; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 204 KB

Cognitive function during chemotherapy f

Cognitive function during chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study

✍ Hess, L.; Huang, H.; Robinson, W.; Johnson, R.; Alberts, D. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Pilot Study of the Prospective Identific

Pilot Study of the Prospective Identification of Changes in Cognitive Function During Chemotherapy Treatment for Advanced Ovarian Cancer

✍ Lisa M. Hess; Setsuko K. Chambers; Kenneth Hatch; Alton Hallum; Mike F. Janicek; 📂 Article 📅 2010 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 196 KB

Changes in supportive care needs after f

Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs

✍ Vanessa L. Beesley; Melanie A. Price; Penelope M. Webb; Peter O'Rourke; Louise M 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB

Doubling time of serum CA125 is an indep

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy

✍ Liz Y. Han; Vasilios Karavasilis; Tom van Hagen; Shibani Nicum; Karen Thomas; Mi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Anemia during adjuvant non-taxane chemot

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

✍ Lorenzo Gianni; Bernard F. Cole; Ilaria Panzini; Raymond Snyder; Stig B. Holmber 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 165 KB